61 results about "Intradermal injection" patented technology

The invention relates to a medical cosmetic material, and provides an agarose composite hydrogel material containing microspheres, the hydrogel material does not lose water during irradiation sterilization, low-cost irradiation sterilization can be used without production under sterile conditions, and the filling effect of the hydrogel can be prolonged due to the addition of the microspheres. The invention further provides an injection containing the hydrogel material, and the injection can be used for subcutaneous and intradermal injection of medical treatment or medical cosmetology to play a role in tissue filling.

The invention belongs to the technical field of medical instruments, and particularly discloses an injection positioning device for the endocrinology department, which comprises a mounting ring and a lifting injection ring for clamping an injection pen, and the lifting injection ring can lift along a limiting column vertically arranged on the mounting ring; a first pressure spring for driving the lifting injection ring to descend is arranged between the mounting ring and the lifting injection ring; the force storage clamping mechanism is used for locking the lifting injection ring at the force storage position, the three-point pressing parallel triggering mechanism is used for sensing the contact state with the skin surface, and the torque releasing mechanism is used for releasing the force storage clamping mechanism according to the state of the three-point pressing parallel triggering mechanism. By arranging a set of stored force releasing mechanism with condition locking and triggering functions, only when the device is pressed and clung to the skin and the axis of the injection pen is vertical to the skin, the locking state is released, so that the stored force releasing mechanism is triggered to drive the injection pen to complete the puncture action, and the intradermal injection risk caused by angle inclination is completely eradicated.

The invention discloses double-stranded siRNA with lipophilic modification and modified siRNA molecules, which achieve excellent in-vivo distribution performance and delivery efficiency through intrathecal injection, intradermal injection and other administration modes, and have good tolerance and safety while effectively knocking down target gene expression. The invention further discloses a preparation method of the siRNA with lipophilic modification, a pharmaceutical composition and application of the siRNA in preparation of drugs for treating TNF-alpha mediated diseases or symptoms.

The invention relates to a targeted YTHDF1-shRNA (short hairpin Ribonucleic Acid) medicine for treating atopic dermatitis and a pharmaceutical composition containing YTHDF1-shRNA and an adeno-associated virus vector. According to the shRNA medicine, the adeno-associated virus serves as a carrier, the effect of inhibiting YTHDF1 expression is achieved through local intradermal injection, atopic dermatitis symptoms are improved, and the shRNA medicine has wide application prospects in the aspect of clinical treatment of atopic dermatitis.

The application belongs to the technical field of medical apparatus and specifically discloses an injection positioning device for endocrinology department, which comprises a mounting ring and a lifting injection ring for clamping an injection pen, the lifting injection ring can be lifted along a limiting column vertically arranged on the mounting ring, a first compression spring for driving the lifting injection ring to descend is arranged between the mounting ring and the lifting injection ring, a force storage engagement mechanism for locking the lifting injection ring at a force storage position, a three-point pressing parallel trigger mechanism for sensing the contact state with the skin surface and a torque release mechanism for releasing the force storage engagement mechanism according to the state of the three-point pressing parallel trigger mechanism are further included. The force storage release mechanism with the conditional locking and triggering functions is arranged, and the locking state is released only when the device is pressed to be close to the skin and the axis of the injection pen is perpendicular to the skin, so that the force storage mechanism is triggered to drive the injection pen to complete the puncture action, and the intradermal injection risk caused by the angle inclination is eliminated.

The present disclosure provides a double-stranded siRNA with lipophilic modification. The modified siRNA molecules exhibit excellent in vivo distribution and delivery efficiency via intrathecal injection, intradermal injection, or other administration routes. The molecules effectively knock down target gene expression while maintaining good tolerability and safety. The present disclosure further provides a preparation method of siRNA with lipophilical modification, a pharmaceutical composition, and application of the same in the preparation of a medicament for treating a TNF-α-mediated disease or disorder.

The invention discloses a 3D nano microneedle electrode for improving glucose monitoring performance and a preparation method and application thereof, and relates to the technical field of biosensing. The 3D nanometer microneedle electrode for improving the glucose monitoring performance comprises a microneedle electrode base material and an electrode sensing material, the microneedle electrode base material is a stainless steel intradermal injection needle, the microneedle electrode base material is filled with a conductive filler, the conductive filler comprises carbon paste and silver paste, and the electrode sensing material comprises an inner layer structure and a surface layer structure. The inner-layer structure is a conductive nano-carrier, and the surface-layer structure is a compound enzyme layer. The invention also provides a preparation method of the 3D nano microneedle electrode for improving the glucose monitoring performance. The utilization rate and catalytic activity of Prussian blue are improved, electron transfer is accelerated, and the problems that a traditional glucose sensor is low in electron transfer efficiency, insufficient in stability and limited in detection range and accuracy are effectively solved.

The utility model discloses an injection needle capable of adjusting injection depth by pressure, which belongs to the technical field of medical instruments and comprises an injection needle seat and an injection needle body, the injection needle seat is fixedly connected with the injection needle body, and a liquid inlet hole is arranged on the injection needle seat. The injection needle body is provided with a middle cavity and a plurality of adjusting holes, the liquid inlet hole is communicated with the middle cavity, the middle cavity is communicated with the adjusting holes, and an injection needle inner cavity is defined by the liquid inlet hole, the middle cavity and the adjusting holes; a needle length adjusting assembly in sliding connection with each adjusting hole is arranged in the adjusting hole, the upper end of each needle length adjusting assembly is communicated with the middle cavity, and the lower end of each needle length adjusting assembly is exposed out of the injection needle body. Under the condition that the skin surface is uneven or the injection angle is inclined, the depth consistency when the steel needle injects liquid medicine into the skin can be achieved.

This invention belongs to the field of biomedical technology, specifically relating to a delivery system for type III collagen mRNA and its applications. The nucleic acid delivery system of this invention includes a delivery carrier and a delivered nucleic acid, wherein the nucleic acid is collagen mRNA, and the delivery carrier includes one or more of modified amino acids, growth factors, and polymeric materials. Through intradermal injection, the delivery system of this invention can be administered to the dermal layer of the skin and enter relevant cells, utilizing endogenous cellular proteins to achieve mRNA transfection, forming natural human type III collagen. This invention avoids the immunogenicity risks and structural inactivation problems associated with exogenous collagen injections, and can efficiently and safely replenish non-regenerative type III collagen in tissues. It can be used for various indications such as treating skin aging, promoting wound healing, reducing scar formation, and improving vascular elasticity.

The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of mesenchymal stem cell spheroids which is topically applied to a target site or administered by subcutaneous or intradermal injection for treating skin wounds or scars. Administering mesenchymal stem cell spheroids to wound or scar areas promotes dermal and subcutaneous recovery within the skin, thereby enhancing skin regeneration, scar healing, recovery, and maintenance of skin volume.

The present invention relates to a drug cartridge for a needle-free injector and a needle-free injector comprising said drug cartridge. The needle-free injector, in a state where a jet opening is in contact with the surface of the skin, ejects a target injection liquid from the jet opening into the epidermis and dermis of the skin; and the drug cartridge of the needle-free injector comprises an accommodating portion and a nozzle portion. The accommodating portion has an accommodating space that accommodates the target injection liquid; the nozzle portion is in fluid communication with the accommodating portion and is provided with the jet opening, and said nozzle portion guides the target injection liquid accommodated in the accommodating portion to the jet opening. The diameter of the jet opening is less than or equal to 0.12 mm. Smaller diameters for the jet opening are more advantageous for intradermal injection, and during the entire injection procedure, the target injection liquid in the accommodating space of the accommodating portion is pressurized to between 10 MPa and 26 MPa, so as to realize stable injection of the target injection liquid into the epidermis and dermis of the skin.

The utility model relates to the technical field of medical instruments, in particular to an intradermal injection auxiliary tool which comprises an elastic clamping ring, the upper end face of the elastic clamping ring is open, holding plates are fixedly connected to the left side and the right side of the upper end face of the elastic clamping ring, holding holes are formed in the right sides of the two holding plates in a penetrating mode, and the holding holes are communicated with the holding plates. During use, the two holding plates are pulled to be far away from each other, an opening in the upper end of the elastic clamping ring is driven to be opened, an injector is clamped into the elastic clamping ring, then the elastic clamping ring is closed, the two holding plates are tightly attached, the two holding holes are aligned, the index finger of a nurse stretches into the holding holes, and then the nurse can hold the injector. The two holding plates are held by the hand, the supporting base makes contact with the skin of a patient, the supporting height of the supporting base and the angle between the needle head and the skin of the patient are 5 degrees, then injection operation is carried out, the angle between the needle head of the auxiliary syringe and the skin of the patient is 5 degrees, and convenience is provided for intradermal injection operation of nurses.

The invention discloses a T cell receptor immune stimulator as well as a preparation method and application thereof, and the immune response generated by a'full-spectrum 'T cell receptor antigen is utilized to realize the elimination and inhibition of self-reactive TCR (T cell receptor), so that the immune regulation effect is realized. The T cell immunostimulant induces immune response through intradermal injection, generates anti-uniqueness T cells aiming at an autoreactive T cell antigen receptor (TCR), selectively kills the autoreactive T cells or inactivates the autoreactive T cells to play a therapeutic role.

The present application relates to a kind of intradermal injection training systems, including wrist model, annular light transceiver component, ultrasonic unit and processing module.In the case where puncture needle pierces wrist model, puncture needle forms first projection in annular light transceiver component under the light irradiation of annular light transceiver component, and forms second projection under the ultrasonic monitoring of ultrasonic unit.Processing module establishes three-dimensional coordinate system based on the data of acquired first projection and second projection to present puncture needle in virtual space in three dimensions.The intradermal injection training system of the present application is provided with processing module that can calculate and simulate the angle and depth of actual puncture needle, by obtaining the first projection and second projection of puncture needle, according to the position, angle and length of projection distribution, it can construct injection angle and depth in three-dimensional level, so as to be in the form of video image or picture in real time by display module Show to training personnel and / or teaching staff, to improve the efficiency and effect of training.

The invention relates to a PTGER4 agonist for treating atopic dermatitis or a medicine for promoting the overexpression of PTGER4, the medicine for promoting the overexpression of PTGER4 is RNA (Ribonucleic Acid) for the overexpression of PTGER4, the sequence of the RNA is shown as SEQ ID NO.1, and the PTGER4 agonist is L-902, 688. According to the PTGER4 agonist and the PTGER4 overexpression adeno-associated virus, the PTGER4 activation or overexpression effect is achieved through local external application or intradermal injection, atopic dermatitis symptoms are improved, and the PTGER4 agonist and the PTGER4 overexpression adeno-associated virus have wide application prospects in the aspect of clinical treatment of atopic dermatitis.

A needle-free injection device suitable for delivering a therapeutic substance into the intradermal space of a patient. The needle-free injection device includes a main spring which can be compressed using one or more handles attached to the device to place the needle-free injection device into an armed configuration. Device embodiments may optionally include an injector tube and associated apparatus which may be moved relative to other device structures when the injector is pressed against the skin of a patient with sufficient force. The disclosed operational switches and release mechanisms cooperate to prevent injection unless the device is properly positioned for an injection. Needle-free injection systems and methods of operating a needle-free injection device are also disclosed.

A method of treating vertigo in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous / intradermal injection. The subcutaneous / intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient.

The present invention relates to a porcine circovirus type 2 infection-preventing vaccine composition for intradermal injection. The porcine circovirus type 2 infection-preventing vaccine composition for intradermal injection, according to the present invention, has been verified to be safe through clinical evaluation, and has been confirmed to induce a higher level of a neutralizing antibody titer compared to an intramuscular injection group. This means that the porcine circovirus type 2 infection-preventing vaccine composition for intradermal injection, according to the present invention, effectively protects against porcine circovirus which is recently prevalent, and thus may be utilized in various ways in the fields of porcine circovirus infection prevention and pig farming.

To provide combination vaccines for swine.SOLUTION: Provided is a combination vaccine for protection against a pathogenic infection with porcine circo virus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo) comprising non-replicating immunogen of PCV2 and non-replicating immunogen of Mhyo. The vaccine is characterized in that it is an oil-in-water emulsion comprising squalane, vitamin E-acetate and silica. In another embodiment, the invention provides a combination vaccine for protection against a pathogenic infection with PCV2 and Mhyo by intradermal administration.SELECTED DRAWING: None

The present invention relates to a transdermal dosage form, for promoting local blood flow, of a dual-acting PDE5 inhibitor / organic nitrate ester, and, more specifically, to: use, for preventing or treating various symptoms or diseases including hair loss, of a compound, or a pharmaceutically acceptable salt thereof, that promotes local blood flow by dual-acting as a soluble guanylate cyclase activator and a phosphodiesterase inhibitor; and a transdermal dosage form thereof. The compound promotes local blood flow so as to exhibit, without side effects, excellent effects of preventing and treating hair loss and other various diseases caused by decreased local blood flow, and, if intradermally injected using a microneedle, exhibits effects, that are remarkably better than those of treatment by application, of preventing and treating hair loss and other various diseases caused by decreased local blood flow even with less treatment frequency, and thus the compound can be effectively used as pharmaceutical and cosmetic compositions for hair loss alleviation and hair growth promotion compositions capable of replacing conventional hair loss therapeutic agents, which had limited application, and also can be used for treating various diseases caused by decreased local blood flow.

Described are compositions, kits and methods for preventing, minimizing the risk of, or treating a microbial infection at a wound or surgical site. The method comprises injecting a combination of a therapeutically effective microdose of a microbial agent and a local anesthetic into the dermis layer of the skin. The composition can be administered by medical personnel, provided by non-clinical personnel, or self-administered.

This invention discloses the application of gels and fibroblasts in the preparation of drugs for treating skin defects, belonging to the fields of biomedicine and tissue engineering technology. Early application provides a moist microenvironment to accelerate epithelial migration and achieve rapid wound closure; later, intradermal injection of fibroblasts promotes collagen remodeling and angiogenesis; ultimately achieving synergistic optimization of early rapid closure and later dermal regeneration.

Disclosed in the present invention is a double-stranded siRNA having a lipophilic modification. The modified siRNA molecule, via intrathecal injection, intradermal injection and other administration modes, achieves an excellent in-vivo distribution performance and delivery efficiency, and has a good tolerability and safety while effectively knocking down the expression of a target gene. Further disclosed in the present invention are a method for preparing the siRNA having a lipophilic modification, a pharmaceutical composition, and the use thereof in the preparation of a drug for treating a TNF-α-mediated disease or condition.

The present invention discloses a double-stranded siRNA with lipophilic modification, and the modified siRNA molecules achieve excellent in vivo distribution performance and delivery efficiency through intrathecal injection, intradermal injection and other administration methods, and have good tolerability and safety while effectively knocking down the expression of the target gene. The present invention also discloses a preparation method of the siRNA with lipophilic modification, a pharmaceutical composition, and its use in the preparation of a drug for treating TNF-α-mediated diseases or conditions.

The invention discloses an auxiliary device for medicine injection in the field of medicine injection auxiliary instruments, the auxiliary device comprises a fixing assembly and a guide assembly, the fixing assembly comprises two connecting plates and a fixing plate fixed between the connecting plates; the guide assembly comprises a guide plate and a guide cylinder, rotating rods are arranged on the two sides of one end of the guide plate, and the two rotating rods are rotationally connected to the opposite faces of the two connecting plates correspondingly; the other end of the guide plate is fixedly connected with a fixing rod, the other end of the fixing rod is fixedly connected with the guide cylinder, the upper surface of the guide plate is provided with a guide groove for a syringe needle to pass through, the guide groove and the axis of the guide cylinder are located on the same straight line, and the upper surface of the guide plate is slidably connected with a connecting block in the length direction of the guide plate. A screw is in threaded connection with the fixing plate and penetrates through the fixing plate to be rotationally connected with the connecting block, and inclination angle scales are arranged at the end, close to the guide cylinder, of the connecting plate. By means of the auxiliary device, medicine can be injected into the skin of the foot or the hand of a dead individual more accurately.

The present invention relates to the use of botulinum toxins for the treatment of hyperpigmentation conditions. The use includes intracutaneously injecting botulinum toxin into the skin of a patient with hyperpigmentation at a specific depth, volume and dose to specifically target the epidermal layer and the upper dermal layer. For example, an intradermal injection of botulinum toxin according to the invention may be used to treat chloasma.

The present invention relates to the use of botulinum toxin for the treatment of hyperpigmentation conditions. The use comprises the intradermal injection of botulinum toxin in the skin of a patient affected with the hyperpigmentation condition at a specified depth, volume and dose, thereby specifically targeting the epidermal and upper dermal layers. For example, the intradermal injection of botulinum toxin according to the present invention may be used in the treatment of melasma.

The present invention relates to a transdermal delivery form of a double-effect PDE5 inhibitor / organic nitrate for enhancing local blood flow, and more particularly, to a transdermal delivery form of a double-effect PDE5 inhibitor / organic nitrate, the present invention relates to the use of a compound or a pharmaceutically acceptable salt thereof for the prevention or treatment of a variety of symptoms or diseases including alopecia using a dual action of a soluble guanylate cyclase activator and a phosphodiesterase inhibitor to enhance local blood flow, and a transdermal delivery form thereof. The compound enhances local blood flow, thereby exhibiting an excellent effect of preventing and treating alopecia and other various diseases caused by a decrease in local blood flow without side effects, and can be easily applied to a patient only with less treatment frequency when intradermal injection is performed using a microneedle compared to application therapy. The present invention relates to a pharmaceutical composition and a cosmetic composition for relieving alopecia and promoting hair growth, which can exhibit a significantly improved effect of preventing and treating alopecia and other various diseases caused by reduced local blood flow, and can be effectively used as a pharmaceutical composition and a cosmetic composition for relieving alopecia and promoting hair growth instead of a conventional alopecia therapeutic agent to which the application thereof is limited. The traditional Chinese medicine composition can also be used for treating various diseases caused by local blood flow reduction.

This invention relates to the field of needle-free injector technology, and in particular to an apparatus and method for needle-free injection of local anesthetics into the dermis for infiltration anesthesia. The apparatus includes a receiving space for containing the anesthetic solution; the injection pressure is 14-21 MPa. This invention allows for the design of different needle-free injectors to address the physiological differences in the dermis between men and women, ensuring precise intradermal injection of the anesthetic solution and avoiding entry into the muscle layer. Furthermore, it results in less pain during injection and a longer duration of effect from the onset and exhaustion of the local anesthetic.

The invention discloses a microneedle capable of realizing intradermal injection, and relates to the field of medical instruments. The needle body creatively adopts a novel structural design, it can be ensured that the piercing tip has a tip outline facilitating piercing, the needle body has a high-strength needle body root support, and due to the fact that the second inwards-concave arc line is an inwards-concave arc, on the basis that the piercing tip and the needle body root support are reliably connected, the piercing tip and the needle body root support can be supported by the second inwards-concave arc line, and the piercing tip and the needle body root support can be supported by the second inwards-concave arc line. Compared with an existing micro-needle which adopts an external expansion arc structure only with an external convex arc, the micro-needle has the advantages that the width of the needle head can be reduced and the needle head can be sharpened on the premise of keeping the size of an injection pore channel unchanged and keeping the distance between the injection pore channel and the front edge unchanged; the pain feeling when the needle penetrates into the skin can be effectively relieved, and meanwhile the puncture effect is not affected; the needle head is narrowed, so that the wound becomes small; the needle body and needle head designed by the invention can meet the requirements of reducing pain and shrinking wounds clinically.